Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IRWD
IRONWOOD PHARMACEUTICALS, INC.
NASDAQ
$4.25
▼ DOWN 1.05% (-0.05)

KEY STATISTICS

Market Cap$706.19 M
52w High$5.78
52w Low$1.05
Dividend Yield—
Frequency—
P/E5.44
Volume504.72K
Shares Out.164.61M

COMPANY

LEADERSHIP

Thomas A. McCourt
CHIEF EXECUTIVE
Thomas A. McCourt

COMPENSATION 2026

Salary$867,568
Stock Awards$411,696
Incentive Plan Pay$650,676
All Other Comp.$18,450
Total$1,948,390

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 3, 2010
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
100

PRICE TARGET

Target High$18.00
Target Low$1.00
Target Median$5.00
Target Consensus$6.68

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$119.99M
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2019-04-02Forward597:500

PRICE

$4.25 ▼ DOWN 1.05% (−$0.05)
OVERLAYS
$4.23$4.26$4.29$4.329:30 AM10:29 AM11:27 AM12:26 PM1:25 PM2:23 PM3:22 PM4.25

About Ironwood Pharmaceuticals, Inc.

https://www.ironwoodpharma.com ↗

Ironwood Pharmaceuticals develops and markets GI products like LINZESS for IBS-C and CIC, and is advancing treatments for visceral pain and biliary cholangitis, with strategic partnerships including AbbVie, AstraZeneca, and Astellas.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT IRONWOOD PHARMACEUTICALS, INC. IS KNOWN FOR

LINZESS (linaclotide)
LINZESS (linaclotide)

LINZESS is a leading prescription medication for adults and now children with IBS-C and CIC, offering a targeted, non-opioid treatment for constipation.

COMPETITORS

COMPETITOR
ABBV COMPARE
ARDX COMPARE
BHC COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Royalty$900K $0 ▼$800K ▲$1.1M ▲
Collaborative Arrangement Collaboration and License Agreements$423K $461K ▲$347K ▼$397K ▲
Collaborative arrangement other agreements$87K $0 ▼— —

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
North America$120.47M $46.07M ▼$105.11M ▲$110.91M ▲
Europe and Other$944K $974K ▲$808K ▼$1.11M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
129
LISTED HERE
26
RANKED BY POSITION SIZE
AFTY
0.76% · 11.0M
XBI
0.22% · 5.9M
VTS.AX
0.00% · 4.8M
XSU.TO
0.02% · 4.2M
FNDA
0.08% · 1.6M
FESM
0.07% · 1.0M
XSPU.L
0.04% · 955.3K
FDLS
1.20% · 682.6K
FDM
1.04% · 636.0K
SFLO
0.31% · 590.2K
DFMC
0.03% · 542.5K
BBP
1.47% · 401.2K
PSC
0.05% · 294.5K
PRFZ
0.04% · 274.3K
FSML
0.70% · 238.5K
GSSC
0.09% · 225.3K
LABU
0.15% · 195.7K
DSMC
0.51% · 174.0K
JPSE
0.10% · 139.2K
EES
0.05% · 81.6K
RSSL
0.02% · 78.5K
SF
SFGV
0.02% · 46.5K
ACSG
0.14% · 16.0K
URTY
0.01% · 6.4K
PQ
PQSG
0.21% · 2.5K
AESG
0.40% · 1.8K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
88.79%
HOLDERS
341
TOP 12 OF 341 · RANKED BY POSITION SIZE
Blackrock Inc.
22.9M sh · $149.16M
Blackrock, Inc.
17.8M sh · $74.89M
Armistice Capital, LLC
16.1M sh · $11.58M
Vanguard Group Inc
16.1M sh · $21.05M
Sarissa Capital Management LP
15.9M sh · $20.85M
Bank Of America Corp /De/
11.7M sh · $15.32M
State Street Corp
8.8M sh · $37.09M
Renaissance Technologies LLC
8.4M sh · $10.94M
Janus Henderson Investors Us LLC
7.9M sh · $135.21M
Aqr Capital Management LLC
7.5M sh · $26.45M
Acadian Asset Management LLC
6.6M sh · $23.07M
Blackrock Fund Advisors
6.5M sh · $98.65M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets5
Debt To Equity1
Price To Earnings3
Price To Book1
Overall Score3

INSIDER TRADES

★
OFFICER: SVP, CMO, HEAD-RES&DRUG
Silber Jeffrey
Purchase · 137.0K shares
2026-07-20
★
Silber Jeffrey
— · —
2026-07-20
★
OFFICER: PFO & PAO
Silver Ronald
Sale · 127.9K shares
2026-07-07
★
DIRECTOR
Moukheibir Catherine
Purchase · 63.5K shares
2026-06-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
MARKET OUTPERFORM 1
EQUAL WEIGHT 1
2 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM Wells Fargo EQUAL WEIGHT

SECTORS PEERS

PEERPRICE
SLN$14.64COMPARE
NPCE$14.76COMPARE
CGC$0.97COMPARE
TKNO$6.91COMPARE
BIOA$9.73COMPARE
CLLS$3.26COMPARE
ACB$3.94COMPARE
LFCR$4.48COMPARE